Bio-related compositions

By developing FEDGAS media, the problem of simulated eating state gastric juice in the prior art is solved, and a stable and repeatable in vitro dissolution medium is provided for drug solubility and dissolution testing to accurately predict the impact of food on drug absorption.

CN113785196BActive Publication Date: 2024-12-03BIORELEVANT COM LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080033356.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-04
Filing Date
2020-04-06
Publication Date
2024-12-03
Estimated Expiration
2040-04-06

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively simulate gastric juice in the eating state, which leads to challenges in the solubility and dissolution test of drugs in the stomach, especially in the in vitro dissolution test, where existing media is unstable and unsuitable for long-term use and cannot be accurately predicted. The effect of food on drug absorption.

Method used

A biorelated dissolution medium of FEDGAS in vitro, containing dispersed fats and carbohydrates, simulates the physicochemical properties of gastric juice after high-fat or low-fat diet, prepared by high-energy input and buffer dilution, ensuring the stability of the medium at 37°C. More than 24 hours, suitable for long-term dissolution testing.

Benefits of technology

It provides a stable and repeatable in vitro dissolution medium that can simulate the physical and chemical changes of human gastric juice after eating, improves the accuracy of drug solubility and dissolution tests, reduces the risk of bioequivalence research, and is suitable for all Solubility analysis of various drugs and dosage forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003335482570000041
    Figure BDA0003335482570000041
  • Figure BDA0003335482570000051
    Figure BDA0003335482570000051
  • Figure BDA0003335482570000231
    Figure BDA0003335482570000231
Patent Text Reader

Abstract

A biorelevant precursor composition, after dispersion, dilution or suspension in an aqueous medium, is suitable for simulating the gastric fluid of a mammal in a fed state, wherein the biorelevant precursor composition comprises a substantially solid / solid concentrate, a viscous gel concentrate or a liquid fat dispersion / concentrate, comprising at least one of the main components selected from any of the following main component groups: i) 1-70 wt% of triglycerides and / or diglycerides and / or monoglycerides or any combination thereof; ii) 1-45 wt% of lecithin and / or lysolecithin; iii) 15-70 wt% of carbohydrates; and iv) 1-70 wt% of water or other aqueous medium. Methods for producing these compositions are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of drug solubility, dissolution and biorelevance testing. The present invention describes concentrates and dissolution compositions for preparing in vitro biorelevance test media. The in vitro media contain biologically relevant dietary components and share the physical and chemical parameters of gastric fluid, particularly human gastric fluid, after consumption. The synthetic in vitro media simulates gastric fluid in the fed state and can be used for biorelevance solubility, dissolution and stability analysis of drugs and dosage forms, in vitro dissolution comparison testing, in vitro and in vivo correlations, and in vitro studies of the effects of food on drugs in simulated gastric fluid. Background Art

[0002] The major dietary components of food include fats (including oils, such as glycerides, and lipids, such as phospholipids), carbohydrates, and proteins, which provide nutrition and support biological function.

[0003] In the stomach, ingested food is stored and digested, and lipophilic components, such as drugs, can be dissolved (partially) in the digested dietary fat along with food components, gastric enzymes, and secretions before the chyme is transferred to the upper small intestine. The upper small intestine includes the duodenum, ileum, and jejunum, where further digestion and absorption occur under the catalysis of enzymes that react to food. In addition, the wetting and solubilization of lipophilic components, including drugs, are assisted by lipid breakdown products that are bound to biosurfactants such as bile salts and lecithin. The residence time in the stomach containing partially digested chyme before entering the upper small intestine may be about 30 minutes to more than 6 hours, depending on the food components and drug / dosage form.

[0004] The gastrointestinal tract (GI) mentioned herein includes the stomach and the upper part of the small intestine. The present invention relates to simulated gastric juice in a fed state induced by, for example, a high-fat (e.g., containing 55g to 65g of fat) or a low-fat diet (e.g., containing 11g to 14g of fat), which is recommended by the FDA for evaluating the effect of food on drugs (Draft Industry Guidelines 2019). The present invention provides a gastric medium for testing in vitro solubility and dissolution in a fed state, and helps to understand the way in which a drug is released from a dosage form in the stomach after eating. The bio-related simulated gastric juice in a fed state of the present invention for in vitro dissolution testing is called FEDGAS. These tests may help predict the effects of food on drug absorption, which may be positive, negative, or unchanged. Solubility and dissolution / dissolution rate are key parameters for oral drug absorption and subsequent bioavailability. Compared with simulated gastric juice in a fasted state, solubility and dissolution tests in a dissolution medium in a FEDGAS fed state can help predict whether oral absorption will be affected by food.

[0005] These tests can also be used to reduce the risk of bioequivalence studies by ensuring that the dissolution profile of the test drug matches that of the reference marketed (innovator) drug.

[0006] The physicochemical properties of the gastric environment, such as pH, buffering capacity, osmotic pressure, ionic strength, and gastric motility, change significantly with food intake. Pharmacokinetic parameters, such as peak concentration (Cmax), time to peak (Tmax), and area under the concentration-time curve (AUC), can be correlated with solubility and dissolution profiles in simulated gastric fluid (FEDGAS). Combining biorelevant in vitro dissolution testing in simulated fed and fasted intestinal fluids with physiologically based pharmacokinetic models, the bioavailability of the drug can be predicted. In the gastrointestinal environment, such as between pH 4.5-6.5, pH-dependent modified and sustained-release dosage forms may have different disintegration times and drug release patterns in vivo, as fed gastric fluid generally spans a wide physiological pH range. This behavior can be reflected in the fed state simulated gastric fluid (FEDGAS) in vitro dissolution media (pH 3, pH 4.5, and pH 6.0) testing. The present invention is also applicable to in vitro dissolution testing of other modified release formulations, including but not limited to, for example, diffusion systems, dissolution systems, osmotic systems, ion exchange resins, flotation systems, bioadhesive systems, and matrix systems.

[0007] The physicochemical stability of FEDGAS does not change in in vitro dissolution tests at 37°C for more than 24 hours. Therefore, the sustained-release dosage form can be tested in FEDGAS dissolution medium at 25°C and 37°C for more than 24 hours, which further highlights the advantages and industrial applicability of the present invention compared to prior art dissolution tests that are generally limited to 8 hours (see Figures 11 and 12). The test medium is particularly suitable for equilibrium solubility testing because equilibrium may take more than 24 hours.

[0008] Therefore, the present invention focuses on a biologically relevant in vitro gastric medium with reproducible standards (eg, particle size and filterability) that more closely mimics and simulates the physicochemical properties of human post-feeding gastric fluid.

[0009] The composition and physical properties of fed gastrointestinal fluid depend on the type of food (see the standard high-fat and low-fat meals recommended by the Food and Drug Administration (FDA) as described in the 2019 draft guidance for evaluating the effects of food on drugs in investigational new drug programs (INDs) and new drug applications (NDAs)) and the length of time in the stomach. In the fasted state, without food, the pH of gastric fluid is usually around 1-3. After eating, the pH rises to around 6 and then returns to an acid-base level between 1-3 within about 6 hours. Changes in gastric pH mainly affect weak acids and weak bases. In the fed state, an increase in pH enhances the solubility of acids and reduces the solubility of bases, but at a pH of 3, the opposite may be true.

[0010] Pharmacopeial media (e.g., USP and EP) that simulate gastric fluid do not contain physiological / biological components (e.g., fat) and are generally not suitable for biorelevant solubility and dissolution testing of water-insoluble drugs.

[0011] In one aspect, the in vitro fed dissolution medium (FEDGAS) derived from the precursor concentrate simulates in vivo gastric fluid after consumption of, for example, an FDA high-fat meal. This high-fat meal is a standard recommended high-fat meal for in vivo drug food effect testing and in vivo food-effect bioequivalence studies in humans.

[0012] On the other hand, the fed gastric medium used for in vitro dissolution testing includes the amount of fat present in the meal. The in vitro dissolution medium prepared from the precursor concentrate may provide an amount of fat similar to the amount of fat in the meal (between 1 g and 200 g).

[0013] It should be understood that the in vitro fed state gastric test media described in the present invention have practical uses and industrial applicability beyond solubility and dissolution testing. For example, the in vitro biorelevant media can be used to test the compatibility of gastric implants, gastric devices, and gastric bands; and to evaluate the stability of probiotic and vitamin products to determine whether they are unstable and can coexist with food in the stomach.

[0014] The present invention relates to the development and provision of in vitro fed state simulated gastric fluid (FEDGAS) based on, for example, FDA high fat and low fat diets and other diet variations (e.g., Klein et al., "Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts." Journal of pharmacy and pharmacology 56(5)(2004):605-610), which are recommended for use in in vivo human studies to evaluate the effects of food on drugs, such as (i) high fat and high calories, (ii) medium fat and medium calories, (iii) low fat and low calories, and (iv) low calorie or high calorie diets with similar fat amounts.

[0015] Prior art

[0016] F.Baxevanis et al. (European Journal of Pharmaceutics and Biopharmaceutics, Vol. 107, 2016, 234-248) describe the physicochemical factors that affect the solubility and dissolution of drugs in various simulated gastric fluids after eating. A comprehensive description of the gastric fluid in a simulated fed state for dissolution testing and drug analysis techniques is given. The feeding conditions have a significant effect on in vitro drug dissolution and subsequent absorption characteristics. It should be emphasized that drug analysis in the gastric medium in the fed state in the prior art may be challenging because most of the analytical schemes used are time-consuming and laborious. Due to the physical properties and chemical composition of the prior art dissolution media, filterability and appropriate buffer (avoiding precipitation and achieving 100% drug recovery) are urgent issues that need to be considered in practice in in vitro tests. Clearly, there is an unmet need for easier-to-use biorelevant dissolution media that better simulate fed gastric fluids and avoid existing problems with prior art in vitro dissolution testing, such as compatibility, precipitation, filterability, and drug recovery at physiological gastric fed pH (e.g., pH 1.5-7.5).

[0017] In Pharmaceutical Research, Vol. 25, No. 7, 2008, 1663-1676 by Jantratid et al., a snapshot fed state simulation medium (FeSSGF) for dissolution testing is proposed, comprising 50% acetate buffer and 50% ultra-high temperature sterilized milk (containing up to 3.5% fat in whole fat ultra-high temperature sterilized milk), and the fat content in FeSSGF is 1.75% at pH 5.0. Table 2 of Jantratid et al. shows three "snapshot" media (early, mid-term, late) compositions of simulated fed gastric fluid, corresponding to pH 6.4, 5 and 3. FeSSGF is an acronym for identifying mid-term fed state simulated gastric fluid at pH 5, 75min to 165min after eating. However, this composition, referred to as mid-term (FeSSGF) in the aforementioned Table 2, essentially contains milk / buffer, which does not have the fat content of a high-fat meal required by the FDA, and is affected by the fat content and quality changes in milk. In addition, the physical stability was also unsatisfactory (see Figure 4 of Jantratid et al.). Table 4 of Jantratid et al. shows the dissolution medium of the upper small intestine under simulated fed conditions, while the present invention describes the medium of the stomach under simulated fed conditions. For the avoidance of doubt, the FEDGAS of the present invention, which simulates the gastric fluid under fed conditions, is not similar to the FeSSIF of the small intestinal fluid under simulated fed conditions (Table 4 of Janitrid et al.) in terms of in vitro dissolution composition.

[0018] US2016 / 0299113A1 describes a solid composition for preparing a biorelevant dissolution medium for simulating intestinal fluid for dissolution testing in fasting and fed states. The patent teaches that the molar ratio of bile salt to phospholipid is 1:1 to 20:1, so the product contains an amount of bile salt that is beyond the scope of the present invention.

[0019] The in vitro dissolution test of simulated gastric fluid in the prior art includes (a commercially available "protein shake" beverage) that contains fat (4.6% w / v total fat), protein, and carbohydrates to simulate fed gastric fluid. This medium is not suitable for in vitro dissolution testing because, like whole milk, it is unstable in the physiological pH range of the fed stomach and is extremely difficult to filter using a 0.45 μm filter (e.g., using a GD / X glass microfiber (GMF) syringe filter).

[0020] Similarly, FeSSGF, which simulates fed gastric fluid, is not suitable as an in vitro dissolution medium (as mentioned above) because it is difficult to filter and its physical properties are unstable throughout the physiological pH range of the stomach. In addition, FeSSGF does not contain the amount of fat indicated in the FDA-regulated high-fat meal.

[0021] Another example of a prior art FeSSGF medium for dissolution studies is the "fed state simulated gastric emulsion" (FeSSGEm), which is an acetate buffer and lipofundin A mixture of 82.5:17.5. The medium includes triglycerides (1.75%), lecithin (about 0.21%) and glycerol (0.44%). It is worth noting that the composition does not contain fat and carbohydrates, especially the high-fat recommended diet recommended by the FDA, and is not stable in the gastric pH range throughout the feeding period (Klein, In vitro lipolysis assay as a prognostic tool for the development of lipidbased drug delivery systems: Martin Luther Universitat Halle-Wittenberg; 2013). Summary of the invention

[0022] Table 1 below summarizes and compares the physicochemical properties and performance of various fed gastric dissolution media. It should be understood that Table 1 includes the fed gastric media FEDGAS of the present invention and clearly shows that the FEDGAS has all boxes checked (+) and therefore meets all the identification parameters that are missing (-) from the known media in the prior art.

[0023] Table 1 - Comparison of physicochemical properties and performance of fed in vitro dissolution media, such as FeSSGF and the in vitro fed gastric medium (FEDGAS) according to the present invention.

[0024]

[0025]

[0026] +Suitable as a test medium

[0027] - Not suitable for use as a test medium

[0028] As shown in Table 1, liquid enteral and parenteral products as well as actual homogenized standard FDA meals have been used as in vitro dissolution media to study simulated gastric fed-state conditions. Nevertheless, extraction issues and the time taken for drug analysis require more user-friendly simulated fed-state gastric fluids that are compatible with the dissolution apparatus and recommended methods in the USP standards. There is little information indicating that prior art dissolution media are suitable for drug dissolution testing at 37°C for more than 4 hours and are also compatible within the physiological fed-state pH range of the stomach between pH 7.5 and pH 1.5, spanning the “early” to “middle” to “late” stages of digestion in the stomach. Testing at three typical pH values ​​within the pH 7.5–1.5 range is necessary so that solubility and dissolution profiles can be monitored when the drug in the fed stomach is in contact with food.

[0029] An object of the present invention is to provide an in vitro dissolution medium containing dietary ingredients, the dietary ingredients mainly comprising fats and carbohydrates, which capture and replicate the physicochemical properties of gastric juice after eating. In addition, when conducting in vivo BA / BE (bioavailability / bioequivalence) studies and studies on the effects of food on drugs in the human body, the dissolution composition generally contains the amount of fat and carbohydrates in a high-fat, high-calorie standard diet recommended by the FDA. There is still an unmet need for an in vitro dissolution medium containing biologically relevant ingredients that reproduce or can reproduce the physical and chemical properties of human gastric juice in a fed state after ingesting a diet containing a variable fat content in the range of 1g to 200g.

[0030] The present invention discloses an in vitro biorelevant dissolution medium specifically designed for testing food effects in the fed stomach, including but not limited to solubility, stability, dissolution profiles of new compounds as well as generic drugs, dissolution comparisons of dosage forms supporting BA / BE studies, probiotics, nutritional supplements, vitamins, gastric implants, compatibility of gastric contents over the entire pH range for device performance and safety testing. In addition to labor savings, consistency and reproducibility, the fed state gastric medium is compatible with post-incubation filtration, thereby allowing HPLC analysis of drug or decomposition products in the filtrate, which has been emphasized in the aforementioned prior art (Baxevanis et al.).

[0031] It is believed that the biorelevant fed gastric medium (FEDGAS) described herein is more suitable for in vitro dissolution testing and in vitro and in vivo correlation studies than the media described in the prior art (e.g., FeSSGF) because FEDGAS simulates in vivo gastric fluid after consuming, for example, an FDA standard high-fat meal.

[0032] Brief description of the invention

[0033] The term "biorelevant concentrate / composition" is also referred to herein as a "biorelevant precursor composition" or "biorelevant precursor concentrate."

[0034] The present inventors have found that an in vitro gastric dissolution medium comprising dispersed fat and carbohydrates mimics the properties of gastric fluid after consumption of, for example, a high fat meal. The fat comprises triglycerides, diglycerides, monoglycerides, lecithin and / or lysolecithin.

[0035] The present invention provides substantially solid / solid-like concentrates, substantially transparent to opaque viscous gel-like compositions (concentrates), and fat dispersions / liquid concentrates containing high levels of fat and carbohydrates, wherein the combination of high energy input and components mainly comprising triglycerides, lecithin and / or lysolecithin and carbohydrates produces a fat dispersion (concentrate) that is easily dispersed in water. These concentrates that are easily dispersed in water are diluted with an aqueous medium comprising, for example, a buffer and an osmotic component to obtain a dissolution medium in the fed state and a fat aggregate with an average particle size of less than 500 nm (Figure 9). Unexpectedly, within at least 24 hours after the medium is prepared, it has typical physicochemical stability in an in vitro dissolution test, and the concentrate has a long-term stability of up to at least 12 months at room temperature.

[0036] Suitable buffers are selected from, but not limited to, acetate, phosphate and citrate buffers to span the physiological gastric pH range of 1.5 to 7.5 in the fed state. Particularly useful pH parameters are pH 3.0, pH 4.5, pH 5.0 and pH 6.0, reflecting the pH of human gastric fluid after ingestion of a high-fat or low-fat meal at different residence times in the fed stomach. In vitro dissolution media prepared from concentrated compositions also avoid problems that arise during analysis, such as filtration and incompatibility with gastric pH throughout the fed state between pH 1.5 and pH 7.5, which have been identified in the prior art and are listed in Table 1.

[0037] The process involves high energy input, controlled evaporation and / or careful addition of targeted amounts of water.

[0038] The process steps include:

[0039] (i) high energy input, such as high pressure emulsification, sufficient to produce fine and substantially uniform fat particles / aggregates having an average diameter of less than 1000 nm, typically less than about 500 nm; and

[0040] (ii) adding water containing at least one carbohydrate such as sugar or directly controlling the addition of an aqueous solution containing at least one carbohydrate such as sugar and then carrying out controlled evaporation, wherein the water content of the obtained target composition is strictly controlled to be between 1.0 wt% and 70.0 wt%, generally between 1.0 wt% and 10.0 wt% for solid / solid concentrates, generally between 10 wt% and 25 wt% for viscous gel concentrates, and generally between 25 wt% and 70 wt% for fat dispersions / liquid concentrates.

[0041] The processes and process steps detailed herein constitute a further aspect of the invention.

[0042] The substantially solid / solid concentrates, viscous gel concentrate compositions and liquid fat dispersion concentrates obtained are concentrates and precursors for preparing biorelevant dissolution media in the fed state as described above.

[0043] The test medium can be prepared by dispersing, diluting or suspending the readily water-dispersible precursor concentrate with an aqueous medium using simple mixing (e.g. a magnetic stirrer) and without any high energy input. The resulting test medium is a stable, homogeneously dispersed fat dispersion that is easily filtered through a 0.45 μm filter.

[0044] Media containing uniformly finely dispersed fat particles are suitable for dissolution testing between pH 1.5 and about pH 7.5, thereby providing pH compatibility within the physiological pH range of the stomach in the fed state, which has hindered the wider use of prior art fed gastric dissolution media. In addition, pH incompatibility, filterability and reproducibility limitations associated with, for example, milk and enteral substitutes have hindered in vitro dissolution and food effect testing using conventional dissolution equipment (including, but not limited to, for example, the USP Dissolution Apparatus 2).

[0045] For solubility testing, volumes of 0.5 ml to 20 ml, more typically 5 ml to 10 ml, can be used to assess kinetic and equilibrium solubility, for example as determined by shake flask methods.

[0046] For USP standard dissolution apparatus 1 and 2, a container with a volume of 250 ml to 1 L, preferably 750 ml to 900 ml, can be used. For in vitro dissolution testing, a micro dissolution container with a smaller volume, usually 50 to 200 ml, can be used.

[0047] In flow cell testing using, for example, a USP Dissolution Apparatus 4, the amount of dissolution medium can be increased to several liters if open loop testing is required.

[0048] The development of a suitable bio-relevant in vitro fed gastric dissolution medium can be used for simple and reliable analytical methods, such as high performance liquid chromatography, which requires the separation of undissolved drugs by filtration, which provides an effective means for testing the effects of food on drugs and pharmaceuticals. Several fed media have been tested in the prior art, such as milk, nutritional beverages, or simulated gastric fluid (FeSSGF) at a fed state of pH 5 to simulate the postprandial state of humans (Table 1). However, to date, no method has been able to satisfactorily represent the actual fed gastric fluid of the FDA after a meal, nor is it suitable for routine laboratory use. The bio-relevant dissolution medium (FEDGAS) provided by the present invention more accurately simulates human gastric fluid after a high-fat meal, which corresponds to pH 6.0 at about 30 minutes and returns to a basal level of pH 3.0 about 6 hours after eating. However, due to changes in dietary composition and the intervariability and variability of human gastric physiology in the fed state, the pH may span a larger range, such as between pH 7.5 and pH 1.5. In one aspect, the present invention provides a biorelevant composition in a concentrate suitable for preparing an in vitro fed state dissolution medium when dispersed or diluted in an aqueous medium for simulating the gastric fluid of a mammal in a fed state.

[0049] In one embodiment of the present invention, the aqueous medium used to disperse or dilute the bioconcentrate composition for preparing an in vitro fed state dissolution medium may contain 3 to 60 times of a dilutable buffer concentrate.

[0050] In one embodiment, the biorelevant precursor composition of the present invention is substantially a solid / solid-like concentrate, a viscous gel-like concentrate or a liquid fat dispersion / concentrate, comprising at least one major ingredient selected from the following groups:

[0051] i) 1-70 wt% of triglyceride and / or diglyceride and / or monoglyceride or any combination thereof;

[0052] ii) 1-45 wt% lecithin and / or lysolecithin;

[0053] iii) 15 to 70 wt% carbohydrates; and

[0054] iv) 1-70 wt% of water or other aqueous medium;

[0055] wherein the weight ratio of total fat (combination of one or more main components from any one of groups i) and ii)) to total carbohydrate (combination of one or more main components from group iii)) is 20:1 to 1:20; and

[0056] The weight ratio of glyceride:lecithin and / or lysolecithin is 45:1 to 1:45; and

[0057] In addition, it also contains at least one additional ingredient selected from the following components:

[0058] (i) fatty acid (0.01-15 wt %);

[0059] (ii) bile acids / salts (0.01-3 wt %);

[0060] (iii) enzyme (0.01-2 wt %);

[0061] (iv) cholesterol, sterol (0.01-5 wt %);

[0062] (v) buffer (0.01-4 wt %);

[0063] (vi) penetrant (0.01-8 wt %);

[0064] (vii) protein (collagen, protein hydrolysate, amino acid) (0.01-30 wt %);

[0065] (viii) mucin (0.1-5 wt %);

[0066] (ix) a viscosity modifier (0.1 to 5 wt %); and

[0067] (x) preservatives, stabilizers (0.01 to 3 wt%), e.g.

[0068] a) Antioxidants,

[0069] b) chelating agents,

[0070] c) inorganic / organic buffers, and

[0071] d) antimicrobial agents;

[0072] All percentages (mentioned above and below) are by dry weight unless otherwise stated.

[0073] In one embodiment of the invention, the aqueous medium used to disperse or dilute the bioconcentrate composition for preparing an in vitro fed state dissolution medium may include:

[0074] (i) buffered solutions to achieve the required pH, buffering capacity, and osmolarity of the biorelevant dissolution medium without further dilution; or

[0075] (ii) sufficient weight / measurement of a biologically relevant concentrate, sufficient weight / measurement of a buffer concentrate, and purified water to achieve the desired pH, buffering capacity, and osmotic pressure, which may be added and / or diluted in any order.

[0076] In another embodiment of the invention, components such as mucins, enzymes (e.g. pepsin and / or pancreatin) and / or proteins and / or amino acids reflecting the content of high-fat and low-fat meals can be added to the in vitro biologically relevant fed gastric dissolution medium during or after the preparation of the fed dissolution medium, respectively. Alternatively, the components can also be added to a buffer concentrate or a diluent buffer.

[0077] Volume reduction and controlled evaporation or titration

[0078] In another aspect, the present invention provides a method for preparing a precursor concentrate, the method comprising processing dietary components, uniformly dispersing and / or homogenizing and / or controlling the water content in the range of 1.0 wt % to 70.0 wt % by evaporation (e.g., vacuum evaporation or thin film evaporation, dialysis, microwave and / or addition or titration) to obtain a substantially solid / solid composition, a viscous gel-like composition and a liquid fat dispersion / concentrate.

[0079] In one embodiment, the substantially solid / solid concentrate typically contains 1 wt% to 10 wt% water or an aqueous medium.

[0080] In one embodiment, the viscous gel concentrate generally contains 10 wt% to 25 wt% water or an aqueous medium.

[0081] In one embodiment, the liquid fat dispersion concentrate typically contains 25 wt% to 70 wt% water or an aqueous medium.

[0082] Method for preparing biorelevant in vitro dissolution media from concentrates

[0083] As explained herein, based on the amount of fat in a recommended FDA standard high-fat or low-fat diet and a replacement diet, a concentrate or biorelevant precursor composition can be converted into a biorelevant in vitro gastric dissolution medium under fed conditions by adding a suitable aqueous medium or diluent. Therefore, in one aspect, the present invention further provides a method for preparing a synthetic bioconcentrate in vitro fed dissolution medium based on the amount of fat in a high-fat to low-fat diet, comprising adding an aqueous medium buffered to pH 1.5 to pH 7.5 or adding 3 times to 60 times the buffer concentrate to the biorelevant precursor concentrate composition of the present invention. The present invention also provides a synthetic in vitro biorelevant fed dissolution medium, which comprises the biorelevant precursor concentrate composition of the present invention and an aqueous medium. The present invention also provides a synthetic in vitro biorelevant fed dissolution medium, which can be obtained by adding an aqueous medium to the biorelevant precursor concentrate of the present invention.

[0084] The aqueous medium includes, for example, purified water, and may also include a buffered aqueous solution, a 3- to 60-fold buffer concentrate, an osmotic component, ethanol, a stabilizer, and an enzyme. The buffer preferably contains one or more inorganic or organic buffers selected from the group consisting of the buffers listed herein.

[0085] Typically, when the bioconcentrate / composition is a liquid fat dispersion concentrate, a substantially transparent to opaque viscous gel-like composition, or a substantially solid / solid-like concentrate, the dispersion or dilution in an aqueous medium comprises contacting the precursor composition with at least the same volume of aqueous medium. Preferably, the precursor composition is diluted with at least 2 to at least 10 times the volume of aqueous medium. For media with low fat content, the present invention also includes higher dilutions (up to 100 times).

[0086] The present invention also provides for the use of a synthetic in vitro fed-state gastric biorelevant dissolution medium in solubility and dissolution testing of reference marketed products and drug products in support of in vivo BA / BE studies.

[0087] In addition to the in vitro solubility and dissolution of test drugs (new compounds and generic drugs) and their dosage forms in biologically relevant media simulating gastric fluid under low-fat fed conditions to explore the effect of food on drugs, the present invention also provides in vitro fed gastric media for compatibility and stability testing with, for example, probiotics, nutrients, vitamins, and gastric devices, including implants, stents and gastric bands, for weight control and weight loss, and dose burst studies with ethanol. DETAILED DESCRIPTION OF THE INVENTION

[0089] The composition of the present invention is a synthetic in vitro biorelevant concentrate that simulates the amount of fat in a diet with different fat contents, as well as the final physicochemical properties of gastric juice after consuming a diet. Fats include triglycerides, diglycerides, monoglycerides, lecithin and / or lysolecithin. The term "biorelevant concentrate / composition" (also referred to herein as "biorelevant precursor concentrate composition") refers to that the biorelevant concentrate composition itself does not necessarily simulate the physiological environment of the stomach. On the contrary, when the bioconcentrate that is easily dispersed in water is diluted, dispersed or suspended in an aqueous medium or with an aqueous medium, it is easy to prepare a reliable gastric medium in a fed state by simple mixing (e.g., a magnetic stirrer) without any high energy input. The resulting medium contains a stable and uniform fat dispersion that is easy to filter through a 0.45 μm filter. First, the biorelevant medium simulates the physiological and physicochemical functions of gastric juice induced by consuming a test diet, and is used for in vitro dissolution and dissolution tests to determine the food effect of the drug.

[0090] The substantially solid / solid concentrate generally contains 1 wt% to 10 wt% of water or an aqueous medium.

[0091] The gel concentrate usually contains 10 wt% to 25 wt% of water or an aqueous medium.

[0092] Fat dispersions / liquid concentrates typically contain 25% to 70% by weight of water or an aqueous medium.

[0093] The bio-related precursor composition of the present invention is usually stored in a container. Typically, the container is a laminated bag or a pouch. The container can be (but not limited to) glass, a suitable plastic bottle (high-density polyethylene, polyethylene, polypropylene, etc.), a suitable metal bottle (aluminum, stainless steel). Typically, the laminated bag or pouch can accommodate about 1g to about 1500g, such as about 5g to about 500g of the bio-related concentrate. Containers up to, for example, 10kg can also be used.

[0094] The biorelevant precursor compositions of the present invention can be stored in a kit together with compositions, such as solid dissolution compositions and / or concentrated buffer solutions, which, when dispersed, diluted or suspended in an aqueous medium, are suitable for simulating, for example, the gastric fluid of a mammal (e.g., human, dog, rabbit, rodent, mouse, ape and pig) in a fed state at a desired physiological pH.

[0095] The kit may also include a filter and a pre-filter, wherein the filter is used to separate undissolved drug particles from a filtrate containing dissolved drugs, wherein the pore size of the filter is, for example, between 0.2 and 1 μm, and the pore size of the pre-filter is, for example, between 1 and 10 μm, and the pre-filter is selected from, for example, glass microfiber, polyvinylidene fluoride, nylon or polyethersulfone.

[0096] As described in more detail herein, the bioconcentrate composition of the present invention comprises uniformly dispersed fat comprising a mixture of triglycerides and / or diglycerides and / or monoglycerides and diacylated phosphatidylcholines (diacyl phospholipids) and / or lysolecithin (monoacyl phospholipids), and carbohydrates and / or sugar alcohols in an aqueous medium, wherein the water content of the concentrate composition is 1.0 wt% to 70.0 wt%.

[0097] The compositions of the present invention may also include a bile salt component in a smaller amount (<3.0%) to reflect the consequences of duodenal reflux.

[0098] The biorelevant precursor composition is surprisingly stable and reproducible for the preparation of biorelevant in vitro fed gastric media (FEDGAS). The biorelevant precursor concentrate exhibited unexpected and surprisingly strong physicochemical properties in continuous stability testing at 22°C for more than 9 months and at 40°C for at least 9 months, indicating the reproducibility of the same preparation of in vitro fed gastric media for drug dissolution testing and (other) industrial applications (see Case Study 2).

[0099] The predictability and user-friendliness of the medium depend primarily on constant physicochemical parameters such as particle size, fat composition, buffering capacity, surface tension, osmotic pressure, wherein the weight ratio of total fat to total carbohydrate content in the medium is 20:1 to 1:20; optionally or preferably, 15:1 to 1:15, or 10:1 to 1:10, or 5:1 to 1:5, or 2:1 to 1:2.

[0100] The surface tension of the gastric dissolution medium in the fed state in vitro is usually between 30 mN / m and 50 mN / m.

[0101] In vitro fed gastric media are easily filterable, have substantially uniform submicron particles, consistently below 1000 nm, preferably below 500 nm, more preferably below 250 nm, still more preferably below 200 nm, typically below 175 nm, e.g. 150 nm, with a narrow size distribution and a polydispersity index (pdi) consistently below 0.2. Consistent physicochemical properties (e.g. particle size, narrow distribution, surface tension, pH compatibility within the physiological pH range of fed gastric fluid between pH 1.5 and pH 7.5, and temperature stability at around 37°C for at least 6 hours) are important.

[0102] Typically, the dissolution medium can be easily filtered using a filter with a pore size of 0.22 to 10 μm, preferably 0.45 to 1.0 μm. At least 20 ml of the dissolution medium can be easily manually filtered using a GE Healthcare WhatmanTM GD / X glass microfiber (GMF) syringe filter with a pore size of 0.45 μm. Typically, the Z-average particle size using photon correlation spectroscopy is less than 200 nm, typically 175 nm. The polydispersity index reflects the particle size distribution is always less than 0.2.

[0103] The biorelevant precursor composition of the present invention is a substantially solid / solid concentrate, a viscous gel concentrate or a liquid fat dispersion concentrate, comprising at least one major ingredient selected from the following major ingredients:

[0104] i) triglyceride and / or diglyceride and / or monoglyceride or any combination thereof (1 to 70 wt %, preferably 3 to 70 wt %, more preferably 5 to 70 wt %);

[0105] ii) lecithin and / or lysolecithin (1-45 wt%, preferably 1-30 wt%, more preferably 1-15 wt%);

[0106] iii) carbohydrates (15-70 wt%, preferably 20-60 wt%); and

[0107] iv) water or other aqueous medium (1-70 wt %, preferably 1-66 wt %, preferably 1-60 wt %);

[0108] wherein the weight ratio of total fat (combination of one or more main components from any one of groups i) and ii)) to total carbohydrate (combination of one or more main components from group iii)) is between 20:1 and 1:20, or preferably between 15:1 and 1:15, or 10:1 and 1:10, or 5:1 and 1:5, or 2:1 and 1:2;

[0109] The weight ratio of glyceride:lecithin and / or lysolecithin is 45:1 to 1:45, or preferably 30:1 to 1:30, or 15:1 to 1:15, or 10:1 to 1:10, or 8:1 to 1:8, or 7:1 to 1:7, or 7:1 to 1:3;

[0110] In addition, it also contains at least one additional ingredient selected from the following components:

[0111] (i) fatty acid (0.01 to 15 wt %, preferably 0.1 to 10 wt %);

[0112] (ii) bile acid / salt (0.01-3 wt %, preferably 0.1-1 wt %);

[0113] (iii) enzyme (0.01-2 wt %, preferably 0.1-1.5 wt %);

[0114] (iv) cholesterol, sterol (0.01 to 5 wt %, preferably 0.01 to 2.5 %);

[0115] (v) buffer (0.01-4 wt %, preferably 0.1-2 wt %);

[0116] (vi) penetrant (0.01-10 wt %, preferably 1-8 wt %);

[0117] (vii) protein (collagen, protein hydrolysate, amino acid) (0.01-30 wt %, preferably 0.1-25 wt %);

[0118] (viii) mucin (0.1-5 wt %, preferably -2.5 wt %);

[0119] (ix) a viscosity modifier (0.1 to 5 wt %, preferably 0.1 to 2.5 wt %); and

[0120] (x) Preservatives, stabilizers (0.01-3 wt %, preferably 0.1-1.5 wt %), such as antioxidants, chelating agents, inorganic / organic buffers and antimicrobial agents.

[0121] Unless otherwise stated, all weight percentages (mentioned above and below) are on a dry weight basis.

[0122] Glycerides

[0123] The bio-related precursor composition of the present invention may comprise at least one triglyceride in an amount of 1 to 70 wt %, preferably 3 to 70 wt %, preferably 5 to 70 wt %. Any synthetic, semi-synthetic or natural triglyceride from any plant or animal source / origin may be used. The triglyceride may be liquid or solid at a relevant temperature, for example from 15°C to 30°C, for example about 20°C. The triglyceride may be selected, for example, from avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, safflower oil, sesame oil, soybean oil (soybean oil) and sunflower oil. Preferred triglycerides include oils that are liquid at 20°C, such as soybean oil (soybean oil), olive oil and rapeseed oil, and oils that are solid at 20°C, such as coconut oil and palm oil. Most preferably, the triglyceride includes olive oil, avocado oil, palm oil. The triglyceride may preferably be a single oil from the same source or a blended oil from different sources / origins. The triglycerides of the present invention also include natural, semi-synthetic or synthetic medium chain triglycerides (MCT) containing fatty acids of 6 to 12 carbons.

[0124] In a preferred embodiment, the fatty acid composition of the biorelevant dissolution medium comprises at least 60% C18, but may be matched to the fatty acid composition of different types of diets.The biorelevant precursor composition of the invention may comprise a partial lipolysis product of at least one triglyceride component as defined herein.

[0125] The bio-related precursor composition may further comprise at least one diglyceride. Any suitable diglyceride may be used in an amount of 1% to 70 wt%, preferably 3% to 70 wt%, preferably 5% to 70 wt%. Any diglyceride as any triglyceride lipolysis product defined herein may be used. Typically, the diglyceride is diolein when used.

[0126] The bio-related precursor composition of the present invention may also include at least one monoglyceride in an amount of 1 wt% to 70 wt% of the total glycerides, preferably 3 wt% to 70 wt%, preferably 5 wt% to 70 wt%. In addition, when included, the amount of monoglyceride is generally no more than 50% of the total glycerides. Any suitable monoglyceride may be used; in particular, any monoglyceride of the lipolysis product of any triglyceride or diglyceride defined herein may be used. Typically, the monoglyceride is monoolein.

[0127] The biorelevant precursor composition of the present invention may also contain at least one fatty acid in an amount not exceeding 15 wt%. Any suitable fatty acid may be used; in particular, any fatty acid of the lipolysis product of any triglyceride, diglyceride or monoglyceride as defined herein may be used. Typically, the fatty acid is oleic acid.

[0128] Lecithin and Lysolecithin

[0129] It should be understood that the description of lecithin includes phospholipids as the main component group of lecithin and neutral lipids, such as glycolipids, fatty acids, triglycerides, etc. Phospholipids are mainly composed of phosphatidylcholine (PC). The purity of phospholipids / lecithin is usually related to the amount of phosphatidylcholine in the mixture; the mixture may also contain phospholipids, such as phosphatidylinositol, phosphatidylserine.

[0130] Phospholipids (lecithin) can have two hydrocarbon tails and are identified as diacylphospholipids. The molecule can also have only one hydrocarbon chain and be identified as monoacylphospholipids. Monoacylphospholipids are commonly referred to as lysolecithins. The hydrocarbon chains of lecithin and lysolecithin can be saturated, such as dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol, and / or unsaturated, such as dioleoylphosphatidylcholine. Lecithin and lysolecithin also include hydrogenated lecithin and lysolecithin, such as hydrogenated soybean lecithin. Lecithin and lysolecithin can be synthetic, semisynthetic or obtained from any plant or animal source, including but not limited to soybean, egg, canola, rapeseed, sunflower or fish.

[0131] The biologically relevant precursor concentrate composition of the present invention contains one or more of the above-mentioned phospholipids and / or one or more of the above-mentioned lysophospholipids.Any suitable lecithin (phospholipid) and / or lysophospholipid (lysophosphatidylcholine) can be used in the form of natural, semi-synthetic or synthetic sources.Charged phospholipids can improve the stability of dispersed fat aggregates.Phosphatidylcholine (lecithin) mainly includes phosphatidylcholine (PC) and a small amount of phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylinositol (PI), phosphatidylglycerol (PG).Lysophospholipid (lysophosphatidylcholine) mainly includes the monoacyl derivatives of lysophosphatidylcholine and a small amount of other phospholipids.

[0132] The phospholipid content of the bioconcentrate precursor composition is 1 to 45 wt%, preferably 1 to 30 wt%, preferably 1 to 15 wt% of lecithin and / or lysolecithin.

[0133] In this mixture, phosphatidylcholine can be about 15wt%~99wt%. Lysophosphatidylcholine (LPC) can be 0.5wt%~85.0wt%. Preferably, phospholipids contain 30.0%~95.0% phosphatidylcholine and 2.0%~70.0% lysophosphatidylcholine. In the present invention, the terms lecithin and phospholipids are interchangeable and include:

[0134] Lecithin and lysophosphatidylcholine or phospholipids and lysophosphatidylcholine in a mixture

[0135] Lecithin (phospholipid) or lysolecithin (lysophospholipid) itself.

[0136] The total amount of lecithin and lysolecithin is 30wt% to 98wt%.

[0137] carbohydrate

[0138] The bio-relevant precursor concentrate composition of the present invention comprises at least one carbohydrate and / or sugar alcohol. Any suitable carbohydrate may also be used, such as saccharides (commonly referred to as sugars) themselves and / or suitable sugar alcohols. For example, saccharides / sugars may be selected from monosaccharides, such as fructose, glucose, galactose, mannose, ribose, etc.; disaccharides may be selected from, for example, sucrose, lactose, maltose, trehalose, etc.; or a combination of monosaccharides and disaccharides.

[0139] The sugar alcohol may be selected from mannitol, lactitol, sorbitol, xylitol, etc. The term sugar alcohol herein includes polyols such as glycerol.

[0140] Preferred concentrates contain sugar itself, and / or a sugar alcohol selected from glucose, fructose, sucrose, lactose, erythritol, maltitol, isomalt, mannitol or xylitol. Combinations of sugars and / or sugar alcohols may also be used.

[0141] The main component group of the carbohydrate component includes saccharides (sugars), sugar alcohols and combinations thereof in appropriate proportions, which can be, for example, combinations of glucose (monosaccharides), fructose (sugar alcohols), sucrose (disaccharides), dextrins or starches (polysaccharides), providing the biorelevant precursor concentrate of the present invention with a water activity of less than 0.86, preferably less than 0.70, thereby inhibiting microbial growth and providing excellent long-term storage properties of the precursor concentrate with a CFU value of less than 10 (Table 2). For solid / solid-like concentrates, the water activity is also less than 0.7. Water activity is a parameter provided by the present invention for characterizing industrial applicability and beneficial effects in the field of biorelevant in vitro dissolution testing and gastric fluid simulation in the fed state.

[0142] Table 2 - Physicochemical properties of biorelevant gelatinous precursor concentrates.

[0143] Microorganisms (CFU / g) <10 water activity 0.5~0.8 Average particle size (nm) <200

[0144] If the water activity is greater than 0.86 or the CFU count is above, for example, >10 CFU / g, the excess microorganisms of the precursor concentrate composition can be reduced by, for example, but not limited to, pasteurization, ultra-high temperature sterilization, sterile filtration, steam sterilization.

[0145] The biorelevant precursor concentrate of the present invention may further comprise a viscosity modifier, including but not limited to digestible or indigestible oligosaccharides and / or polysaccharides. For example, the polysaccharide may be starch, modified starch, dextrin, cellulose, polydextrose, pectin, galactomannan, alginate, etc., and / or semi-synthetic forms such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, chitosan, etc.

[0146] The precursor concentrate of the present invention comprises a total fat:carbohydrate ratio in the range of 20:1 to 1:20, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 5:1 to 1:5, preferably 2:1 to 1:2.

[0147] When the readily water-dispersible precursor concentrate is diluted or dispersed in an aqueous medium, the proportions in the resulting in vitro biorelevant gastric dissolution medium under fed conditions remain unchanged.

[0148] fatty acid

[0149] The biorelevant precursor concentrates of the present invention may comprise additional components further comprising free fatty acids, such as oleic acid, lauric acid, linoleic acid, stearic acid and palmitic acid and salts thereof.

[0150] Bile salts

[0151] The bio-related precursor concentrate of the present invention may include additional components, such as bile salts. Any suitable bile salt can be used. Suitable bile salts include sodium cholate, sodium taurocholate, sodium glycocholate, sodium deoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium choline sarcosinate, sodium N-methyltaurocholate and its free acid, and combinations thereof. Preferably, the bile salt is selected from sodium cholate, sodium taurocholate and sodium glycocholate. More preferably, the bile salt is sodium taurocholate.

[0152] Buffer solution

[0153] The biorelevant precursor concentrate of the present invention may contain a buffer and an osmotic agent. However, the buffer, preferably a buffer concentrate or a buffer solution, is added / added to the bioconcentrate composition or the simulated dissolution medium of the in vitro bioconcentrate in the fed state. More preferably, the buffer is added using a dilutable concentrate that requires from 3 to 60 times, preferably from 5 to 40 times, more preferably from 15 to 30 times dilution.

[0154] The buffer concentrate can be added to the bioconcentrate composition; or alternatively, the biorelevant concentrate composition can be added to the buffer concentrate in the reverse order to provide an in vitro fed state dissolution medium at the desired pH (pH 1.5-7.5) and buffer capacity (5-100, preferably 10-30, 15-30 mM / ΔpH).

[0155] In addition, purified water can be added to the mixture containing the bioconcentrate and the dilutable buffer concentrate to prepare the in vitro fed dissolution medium of the present invention, with a desired target pH between 1.5 and 7.5 for dissolution testing. The biorelevant precursor concentrate composition, (ii) the buffer concentrate and (iii) purified water can be added / combined in any order to prepare the in vitro fed gastric dissolution medium at the desired pH for in vitro dissolution testing.

[0156] Buffer concentrate

[0157] A dilutable 25-fold buffer concentrate containing appropriate amounts of sodium chloride, citric acid, and sodium citrate (amounts from Table 6) was prepared by dissolving the buffer and osmotic agent (sodium chloride) in purified water.

[0158] Prepare 900 ml of in vitro test medium by the following method:

[0159] 1) Weigh 36.8 g of 25-fold diluted buffer concentrate (pH 3) and place it in a suitable container;

[0160] 2) Add 732.6 g of purified water;

[0161] 3) Add 153.0 g of FEDGAS gel;

[0162] 4) Stir until the dispersion is completely uniform.

[0163] The resulting in vitro test medium had a pH of 3.0 and a buffer capacity of typically 22 mM / ΔpH.

[0164] The buffer concentrate and the biologically relevant precursor concentrate composition are placed in separate containers and combined in a manner as described for preparing an in vitro fed gastric medium.

[0165] The two separate containers may be included in a kit together with a filter for conducting in vitro solubility and dissolution testing.

[0166] Any suitable buffer may be used.Suitable buffers include inorganic buffers selected from sodium dihydrogen phosphate; acetic acid; hydrochloric acid; maleic acid; citric acid; lactic acid; potassium dihydrogen phosphate; trisodium citrate; sodium acetate trihydrate; imidazole; sodium carbonate; sodium bicarbonate; sodium cacodylate; sodium barbital; phosphates such as Na2HPO4, NaH2PO4, K2HPO4 and KH2PO4; sodium hydroxide and / or at least one organic buffer selected from 2-(N-morpholino)ethanesulfonic acid (MES); bistrimethylammonium (Bis Tris); 2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]acetic acid (ADA); N-(2-acetamido)-2-aminoethanesulfonic acid (ACES); 1,3-bis(tris(hydroxymethyl)methylamino)propane; piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES); 2-(carbamoylmethylamino)ethanesulfonic acid (ACES); 2-hydroxy-3-morpholinopropanesulfonic acid (MOPSO); choline chloride; choline chloride hydrochloride; 3-morpholinopropane-1-sulfonic acid (MOPS); bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES); 2-[[1,3-di [Hydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES); 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES); [3-bis(2-hydroxyethyl)amino-2-hydroxypropane-1-sulfonic acid] (DIPSO); [3-bis(2-hydroxyethyl)amino-2-hydroxypropane-1-sulfonic acid] (MOBS); acetylaminoglycine; 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-hydroxypropane-1-sulfonic acid (TAPSO); 2,2′,2″-nitrile triol (ethanol monool) (TEA); piperazine-N,N '-bis(2-hydroxypropanesulfonic acid) (POPSO); 4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) (HEPPSO); 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (HEPPS); N-[tris(hydroxymethyl)methyl]glycine (N-tris(hydroxymethyl))(methylglycine, Tricine); tris(hydroxymethylaminomethane) (tromethamine, Tris); glycineamide; glycine; glycine; histidine; N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (HEPBS); 2-(bis(2-hydroxyethyl)amino)acetic acid (N-di(hydroxyethyl)amino)acetic acid) at least one of: (1,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO); (2-(1,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid, CAPSO free acid (CAPSO); (3-(cyclohexylamino)-1-propanesulfonic acid (CAPS); and (4-(cyclohexylamino)-1-butanesulfonic acid (CABS).

[0167] Penetrant

[0168] The present invention includes the use of osmotic agents to adjust the osmotic pressure of the dissolution medium to simulate the osmotic pressure of gastric juice in the fed state after a meal (e.g., FDA meal). Osmotic agents include, but are not limited to, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, hydrochloric acid, and sodium hydroxide, and combinations thereof. Carbohydrates and buffers may also help to adjust the total osmotic pressure of the in vitro dissolution medium. Osmotic agents may be added to the biorelevant precursor concentrate composition, or preferably to the buffered concentrate. The osmotic pressure of the dissolution medium in the fed state ranges from 200 to 800 mOsm / L, typically 300 to 600 mOsm / L. After a meal, the osmotic pressure of gastric juice in the stomach with a high-fat diet is generally higher than the osmotic pressure after a low-fat diet is eaten. In addition, the osmotic pressure is affected by food capacity and residence time in the stomach. The osmotic pressure of gastric juice in the fed state in vivo, which can be simulated in the gastric medium in the fed state of the present invention, is generally between 400 mOsm / L and 550 mOsm / L.

[0169] Enzymes

[0170] If desired, additional components, for example enzymes such as gastric lipase and / or pepsin, may be added to the actual dissolution medium rather than to the concentrate.

[0171] Preservatives and stabilizers

[0172] Examples of antioxidants include, but are not limited to, ascorbic acid, ascorbyl palmitate, vitamin E and esters, carotenoids, vitamin A. Chelating agents include, but are not limited to, dimercaprol, disodium EDTA, deferoxamine, citrate. Organic / inorganic buffers are listed in the buffer section. Antimicrobial agents include, but are not limited to, thimerosal, sodium azide, butylated hydroxytoluene, butylated hydroxyanisole, sorbic acid.

[0173] In a preferred biorelevant precursor concentrate composition:

[0174] (i) at least one triglyceride selected from soybean oil, olive oil, rapeseed oil, coconut oil, avocado oil and palm oil;

[0175] (ii) the at least one diglyceride is selected from the group consisting of glyceryl dioleate, glyceryl distearate, glyceryl dilaurate and linoleic diglyceride;

[0176] (iii) the at least one monoglyceride is selected from glyceryl monooleate, glyceryl monostearate, glyceryl monolaurate and linoleic acid monoglyceride;

[0177] (iv) at least one component selected from phosphatidylcholine and / or lysophosphatidylcholine comprises at least 40 wt % of phospholipids and / or at least 40 wt % of lysophospholipids;

[0178] (vi) at least one sugar and / or sugar alcohol including glucose and fructose and / or sorbitol;

[0179] (vii) at least one polysaccharide comprises starch, modified starch and / or dextrin,

[0180] The ratio of total fat to total carbohydrates is 20:1 to 1:20, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 5:1 to 1:5, preferably 2:1 to 1:2; in addition, the ratio of glyceride to lecithin and / or lysolecithin is between 45:1 and 1:45, preferably 30:1 to 1:30, preferably 15:1 to 1:15, preferably 10:1 to 1:10, preferably 8:1 to 1:8, preferably 7:1 to 1:7, preferably 7:1 to 1:3.

[0181] In particularly preferred biorelevant precursor compositions:

[0182] i) the at least one triglyceride comprises olive oil;

[0183] ii) at least one diglyceride comprises glyceryl dioleate;

[0184] iii) at least one monoglyceride comprises glyceryl monooleate;

[0185] (iv) at least one component selected from lecithin and / or lysolecithin comprises at least 15 wt % of phosphatidylcholine (PC) and / or at least 0.5 wt % of lysophosphatidylcholine (LPC);

[0186] (vi) the at least one sugar comprises glucose, fructose and sucrose;

[0187] (vii) at least one polysaccharide comprises dextrin,

[0188] The total amount of fat: carbohydrate is 20:1-1:20, preferably 15:1-1:15, preferably 10:1-1:10, preferably 5:1-1:5, preferably 2:1-1:2; in addition, the ratio of glyceride: lecithin and / or lysolecithin is between 45:1-1:45, preferably 30:1-1:30, preferably 15:1-1:15, preferably 10:1-1:10, preferably 8:1-1:8, preferably 7:1-1:7, preferably 7:1-1:3.

[0189] The biorelevant precursor compositions of the invention may be modified to meet desired physicochemical properties, particularly the fat content of the composition, which may be, for example, a variation of a standard FDA high fat diet.

[0190] It is within the scope of the present invention to adjust and select the total fat and carbohydrate content in the concentrate for preparing a dissolution medium that simulates the postprandial simulated fed state gastric medium having a target fat value.

[0191] Typically, the water content of the composition is controlled between 1.0% and 25.0% to form substantially solid / solid-like and gel-like liquid concentrates. The water may be removed by evaporation, for example by vacuum assisted drying or by freeze drying, such as freeze drying.

[0192] The content of bile salt in the composition of the present invention is calculated as the amount of intestinal fluid refluxed from the duodenum. When bile salt is contained, the amount of bile salt in the composition of the present invention is less than 3.0 wt%, usually less than 1.0 wt%.

[0193] As an example and not a limitation, the following is an explanation of typical examples of the present invention. Table 3 shows typical examples of concentrated compositions and ranges of typical components. The composition may contain lecithin and / or lysolecithin with different lecithin contents (purities) in the mixture.

[0194] Freeze-fracture of a viscous gel-like precursor of a biologically relevant concentrate is shown in Figure 10.

[0195] Examples of actual dissolution media are shown in Table 8.

[0196] Table 3 - Typical composition of precursor compositions / concentrates

[0197] Element Concentration % (weight / weight) Glycerides 35 (between 1.0% and 70%) Lecithin* 4 (between 1.0% and 45%) carbohydrate 39 (between 15.0% and 70%) Bile salts 0.2 (between 0.01% and 3%) Stabilizer** 0.9 (between 0.01% and 3%) water 17.0 (between 1.0% and 70%)

[0198] *(lecithin and / or lysolecithin)

[0199] ** Optional Table 3 shows the preparation and composition of the in vitro dissolution media for the bioconcentrate composition preparation.

[0200] The amount of total fat in the biorelevant precursor concentrate of the present invention is generally controlled such that when the precursor is dispersed, diluted or suspended in an aqueous medium to obtain a biorelevant medium, the fat concentration is between 0.5% and 20% w / v.

[0201] More typically, the amount of fat in the biorelevant precursor concentrate is controlled so that when the precursor composition is dispersed, diluted or suspended in an aqueous medium, a fat concentration of 4.0% w / v to 20.0% w / v, preferably 5% to 15% w / v, preferably 6% to 10% w / v is obtained, thereby obtaining a biorelevant medium modeled after high-fat and low-fat FDA recommended standard diet variants. In addition, the amount of fat and the amount used can be adjusted and selected to take into account other variants, i.e., medium fat, low-fat variants, very high fat content up to 15% and very low fat content as low as 0.1% are also within the scope of the present invention.

[0202] Table 3 lists the main ingredients in a typical concentrated composition of the present invention. Variable fat content of the desired in vitro test medium can be obtained by selecting components and adjusting the dosage from Table 3, thereby providing a concentrated composition for dilution and preparation of test media for in vitro dissolution, solubility and stability testing of drugs and drug products. Testing in in vitro dissolution media also evaluates potential food effects on drugs and pharmaceuticals due to fat content at the physiological pH of the stomach or beverages / drinks containing fat (e.g., tea containing whole or low-fat milk).

[0203] Typical methods of making precursor compositions

[0204] Step 1

[0205] Weigh components and add to appropriate reactor or process vessel:

[0206] - 66kg of purified water

[0207] -**Stabilizer 0.8kg

[0208] **Optional

[0209] Suitable reactors include, but are not limited to, evaporators, thin film evaporators, microwave ovens, and vacuum assisted reactors. The stirring speed of the solution is between 50 and 10,000 rpm, preferably between 50 and 2,000 rpm, preferably between 50 and 500 rpm, and maintained at 15 to 80° C., preferably between 30 and 80° C., and more preferably between 40 and 70° C.

[0210] Step 2

[0211] When the solution of step 1 is stirred evenly, add the following components:

[0212] -***Lecithin 4.50kg

[0213] - Bile salt 0.16kg

[0214] ***Lecithin and / or lysolecithin.

[0215] The suspension of step 2 is stirred at a temperature of 15-80° C., preferably 40-70° C. and 50-30000 rpm, preferably 100-10000 rpm, preferably 200-5000 rpm. A slight vacuum is maintained until all components are fully hydrated.

[0216] Step 3

[0217] When the suspension in step 2 is stirred evenly, add the following components:

[0218] -****Glycerin 28kg

[0219] ****Triglycerides.

[0220] Step 4

[0221] The suspension of step 3 is stirred at a temperature of 15-80° C., preferably 30-80° C., preferably 40-70° C. and 50-30000 rpm, preferably 100-10000 rpm, preferably 200-5000 rpm to obtain a uniform fat dispersion with a particle size of about 0.5-5 μm.

[0222] Step 5

[0223] The fat dispersion from step 4 may be further processed using a device selected from a high shear mixer, a high pressure homogenizer, a microfluidizer, an ultrasonic homogenizer or any other suitable high energy homogenizer.

[0224] Step 5 gave 99.5 kg (yield) of homogenised fat dispersion and the components shown in Table 4, with an average diameter of 1000 nm, typically below about 500 nm.

[0225] Transfer the homogenized fat dispersion to a suitable reservoir or container.

[0226] Table 4 - Typical examples of components in the homogenized fat dispersion at the end of step 5.

[0227] Element Concentration %(w / w) water 66 Glycerides 28 Lecithin*** 4.5 Bile salts 0.16 Stabilizer** 0.8

[0228] **Optional

[0229] ***Lecithin and / or lysolecithin

[0230] Step 6

[0231] The following components were added to the reactor in step 1:

[0232] -Carbohydrates***22.10kg

[0233] -Dextrin 1.16kg

[0234] ***Invert sugar

[0235] The solution is stirred and heated to 20-80°C, usually 50-70°C. Vacuum is applied to start evaporation, the vacuum degree is usually 10-1000 mbar, preferably 50-200 mbar. The water content at this stage is controlled between 1-70 wt%, usually 15-30 wt%.

[0236] Step 7

[0237] The homogenized fat dispersion previously stored in the reservoir is continuously added to the reactor. The fat dispersion is added at a controlled flow rate of 0.1 to 10 L / min, for example 0.1 to 5 L / min, consistent with the evaporation rate under a vacuum of 10 to 1000 mbar. During the continuous addition of the homogenized fat dispersion, the water content of the mixture in the reactor is preferably between 5% and 70%, preferably maintained between 10% and 40%.

[0238] At the end of step 7, the concentrate composition is in the form of a substantially solid / solid concentrate, a substantially gel concentrate or a liquid fat dispersion / concentrate, depending on the target water content, which is generally between 1 and 70% by weight, between 10 and 25% for viscous gel concentrates as shown in Table 5, between 1.0 and 10.0% for solid / solid concentrates and between 25 and 70% for fat dispersion / liquid concentrates.

[0239] Table 5 - Typical examples of gelatinous precursor compositions at the end of step 7

[0240] Element Concentration %(w / w) water 17 Glycerides 35.2 Lecithin*** 5.8 Bile salts 0.2 Stabilizer** 0.9 carbohydrate 41.1

[0241] **Optional*** Lecithin and / or lysolecithin

[0242] Packaging of precursor compositions

[0243] The gel-like concentrate / composition obtained in step 7 is filled into a suitable container. The container may be (but is not limited to) a sachet, a pouch, a suitable plastic bottle (high-density polyethylene, polyethylene, polypropylene, etc.), a suitable metal bottle (aluminum, stainless steel, etc.).

[0244] The composition is preferably vacuum packed or sealed under an inert gas blanket, such as nitrogen.

[0245] The gelatinous concentrate may be filled and / or packaged in single-dose or multi-dose containers, for example suitable containers having a capacity of up to 10 kg.

[0246] Biorelevant media preparation

[0247] As described in the manufacturing method, the synthetic bio-relevant aqueous medium is obtained by adding an aqueous medium to the bio-relevant gel composition / concentrate in Table 5. The aqueous medium includes, but is not limited to, for example, purified water, an aqueous medium containing a buffer, and an osmotic component. The citrate buffer exemplified in the examples can be replaced by other combinations, such as an acetate buffer at a pH of 5 and a phosphate buffer at a pH of 3. In the dissolving composition of the present invention, additional components, such as enzymes, such as gastric lipase, as well as osmotic agents and buffers, may also be present.

[0248] Typically, biorelevant dissolution media are prepared from the concentrates in Table 5 as follows, for example, to prepare 900 ml of media for a high-fat FDA diet:

[0249] 1- Add approximately 600 g of water and appropriate buffering ingredients for the desired pH to a container.

[0250] 2- Add 152.3 g of the concentrate shown in Table 5 to the container.

[0251] 3- Add the remaining purified water (763.62 g total water) to make up the volume.

[0252] 4- Add a magnetic stir bar and stir until all ingredients are thoroughly mixed.

[0253] 5- Check if the pH is 4.5.

[0254] The typical examples in Table 6, Table 7 and Table 8 below can be obtained using the above preparation method.

[0255] Table 6 - Typical examples of biorelevant concentrate dissolution media at pH 3 prepared from biorelevant concentrates and aqueous buffer solutions.

[0256]

[0257]

[0258] Table 7 - Typical examples of biorelevant concentrate dissolution media at pH 4.5 prepared from biorelevant concentrate and aqueous buffer solution.

[0259]

[0260] Table 8 - Typical examples of biorelevant concentrate dissolution media at pH 6 prepared from biorelevant concentrates and aqueous buffer solutions.

[0261]

[0262]

[0263] The dissolution medium can also be prepared from the individual components by weighing them separately into the buffer solution and then homogenizing them as shown in Table 9a.

[0264] Table 9a - Typical dissolution media comprising individual components in aqueous buffer solution at pH 4.5.

[0265]

[0266] **Optional

[0267] Prepare the biorelevant dissolution medium shown in Table 9b as follows to prepare, for example, 900 ml of medium for a low-fat FDA diet:

[0268] 1- Add approximately 600 g of water and appropriate buffering ingredients for the desired pH to a container.

[0269] 2- Add 76.15 g of the concentrate in Table 5 to the container.

[0270] 3- Add the remaining purified water to make up the volume (a total of 889 g of water needs to be added).

[0271] 4- Add a magnetic stir bar and stir until all ingredients are thoroughly mixed.

[0272] 5- Check if the pH is 4.5.

[0273] Table 9b - Representative example of a biorelevant concentrate dissolution medium at pH 4.5 simulating a low fat FDA meal prepared from a biorelevant concentrate and an aqueous buffer solution.

[0274]

[0275] The biorelevant dissolution media shown in Table 10 were prepared as follows, for example, to make 900 ml of a double high fat FDA diet medium:

[0276] 1- Add approximately 500 g of water and appropriate buffering ingredients for the desired pH to a container.

[0277] 2- Add 304.59 g of the concentrate shown in Table 5 to the container.

[0278] 3- Add the remaining purified water (a total of 610.33 g of water is required) to make up the volume.

[0279] 4- Add a magnetic stir bar and stir until all ingredients are thoroughly mixed.

[0280] 5- Check if the pH is 4.5.

[0281] The following typical examples in Table 10 were obtained using the above preparation method.

[0282] Table 10 - Representative example of a biorelevant concentrate dissolution medium at pH 4.5 simulating a double high fat FDA meal prepared from a biorelevant concentrate and an aqueous buffer solution.

[0283]

[0284]

[0285] Table 11 shows typical physicochemical properties of the previously prepared media.

[0286] Table 11 - Physicochemical properties of typical media used in the dissolution media prepared as shown in Tables 9 and 10

[0287]

[0288] Biorelevant dissolution media simulating fed gastric fluid

[0289] Biorelevant dissolution media can also be prepared in-house by mixing all the components in Table 5 with a predetermined amount of water to obtain the target content of the biorelevant dissolution media. The fat content of the media is 20-100 g in 500 ml of media (U.S. Pharmacopoeia Dissolution Apparatus 2), depending on the amount of concentrate used in Table 5 and the drug dose in the dissolution test. Buffer salts and additional ingredients can be added before or after the lipophilic components are dissolved or suspended in the aqueous medium.

[0290] However, homemade dissolution media do not have the stability and storage properties of concentrates. Therefore, homemade media must be used within 24 hours because they are susceptible to microbiological, physical, and chemical spoilage, making them less suitable as dissolution media in terms of reliability, consistency, and reproducibility.

[0291] Case Studies

[0292] The case study described below demonstrates the effectiveness of the present invention in evaluating the effects of food on a pharmaceutical product in the stomach.

[0293] In case studies 1 to 4, FEDGAS media at pH 6, pH 5, and pH 3 were prepared by adding an appropriate amount of purified water, adding the corresponding buffer concentrate, and adding an appropriate amount of biorelevant precursor concentrate in a suitable container and mixing with a magnetic stirrer until homogeneous.

[0294] Case Study 1 – Dissolution of exemestane (25 mg) tablets (trade name: Aromasin, an immediate-release formulation of a poorly soluble neutral compound).

[0295] Gastric media under three biologically relevant fed states at pH 6, pH 5, and pH 3 were prepared using the compositions in Table 5.

[0296] The media at these three pH values ​​were characterized by measuring pH, buffering capacity, particle size (Z-average and polydispersity using nanosize), and surface tension (Kruss surface tension K6).

[0297] The media was stable at time point 0 and physically stable after 24 hours. Likewise, key physicochemical properties remained unchanged after 24 hours.

[0298] The dissolution of exemestane (4 x 25 mg tablets) in the media was performed using a USP 2 dissolution apparatus at 75 rpm (n = 6 vessels). Samples of three biorelevant media were taken from the dissolution vessels and filtered through a 0.45 μm nylon filter with a prefilter at 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 45 min, 60 min, 90 min and 120 min and analyzed for exemestane content by HPLC.

[0299] The results of these dissolution studies were Figure 1 shown.

[0300] Consistent with the neutral chemical structure of exemestane, it can be seen that exemestane is insensitive to different pH values, and the three dissolution profiles are very similar. Within 30 min, more than 80% of the drug was dissolved in the three media.

[0301] Case Study 2 - Simulated gastric concentrates stored at 40°C for 9 months in the fed state.

[0302] The biorelevant concentrates were stored at 22°C and 40°C for nine months and the studies in Case Study 1 were repeated using media prepared from the stored precursor concentrates. The ease of dispersibility of the fresh and stored precursor concentrates in aqueous media was very similar.

[0303] Unexpectedly, the dissolution profiles of the test media at the three pH values ​​were found to be identical to those of the media prepared from the freshly prepared precursor concentrate.

[0304] Case Study 3 -Dissolution of cinnarizine (basic drug).

[0305] The dissolution of Sturgeron (15 mg cinnarizine immediate release tablets) was tested in fasted gastric media (control experiment) and compared in fed gastric media at pH 6, pH 5 and pH 3 using the same dissolution setup as previously described.

[0306] Figure 2 Dissolution profiles in fasted state gastric media are provided.

[0307] The dissolution profile of this drug product in fasting gastric media showed that this basic drug cinnarizine rapidly dissolved in the fasting stomach. The control experiment showed that within 30 minutes, nearly 90% of the drug was dissolved.

[0308] In contrast, Figure 3 As shown in Figure 2, this basic drug exhibits slower drug solubility in all fed gastric media (in the pH range from pH 6 to pH 3). There is also a trend for faster dissolution of cinnarizine at lower pH (i.e., the dissolution rate increases when the drug spends a longer time in the simulated fed medium), which reflects the pH of gastric fluid at the end of gastric emptying.

[0309] These in vitro dissolution profiles can also be used with modeling software to better simulate how the drug behaves in the stomach and how the drug (dissolved or suspended) is presented to the small intestine as the stomach empties. Combined with dissolution profiles in small intestinal fluids (fed and fasted), these inputs can more accurately predict in vitro-in vivo correlations, leading to more efficient development of drug products.

[0310] Case Study 4 -Dissolution of mefenamic acid (acidic drug).

[0311] Dissolution of mefenamic acid hard capsules in fasted state gastric media (control) was compared to biologically relevant fed state gastric media at pH 6, pH 5, and pH 3 using the apparatus and methods described in Case Study 1.

[0312] Referring to Figure 4, dissolution in the fasted state gastric medium was negligible even after 2 hours of dissolution. Even after 2 hours of dissolution, less than 0.1% of the drug dose was dissolved.

[0313] In stark contrast to the fasted gastric medium, mefenamic acid dissolves more rapidly in the biologically relevant fed gastric medium (see Figure 5). Dissolution of mefenamic acid in the fed gastric medium at pH 6 (simulating the conditions immediately after ingestion of an FDA high-fat meal), pH 5 (simulating the conditions approximately 1-3 hours after ingestion of an FDA high-fat meal), and pH 3 (simulating the conditions approximately 4-5 hours after ingestion of an FDA high-fat meal) reached approximately 45%, 25%, and 10% of the dose within 30 minutes, respectively.

[0314] Case Study 5 -Dissolution of danazol capsule acid (neutral drug).

[0315] Dissolution of danazol (100 mg) hard capsules was performed in fasted state gastric media (control) and compared to biologically relevant fed state gastric media at pH 6, pH 4.5 and pH 3, using the setup and methods described in Case Study 1.

[0316] Referring to Figure 6, dissolution in fasted gastric media was negligible even after 2 hours of dissolution. Even after 2 hours of dissolution, less than 0.2% of the drug dose was dissolved.

[0317] In stark contrast to fasted gastric media, the dissolution rate of danazol in the biologically relevant fed gastric media was quite rapid (see Figure 7). In fed gastric media at pH 6, pH 4.5, and pH 3, dissolution reached approximately 55% of the dose within 60 min.

[0318] Case Study 6 – The physicochemical properties of FEDGAS dissolution medium were examined using dissolution of megesterol acetate capsules stored at room temperature for 72 hours.

[0319] FEDGAS medium at pH 6, pH 4.5 and pH 3 is prepared by adding appropriate amount of water, adding corresponding buffer concentrate and adding appropriate amount of bio-related precursor concentrate that is easy to disperse in water and mixing with magnetic stirrer until uniform. These three media are stored at room temperature for up to 72 hours. After medium preparation using megestrol acetate capsules (160mg) in 900ml medium in a container, it is dissolved in each medium at t=0, t=24 hours, t=48 hours and t=72 hours. The dissolution test results are shown in Figure 8. The pH value, buffering capacity, surface tension and particle size (Z-average value) of FEDGAS pH 6 and FEDGAS pH 3 were measured at t=0 and t=72 hours. The results are shown in Table 12.

[0320] The results showed that the dissolution profiles of megestrol acetate hard capsules were identical for all three media at four time points. This study showed that the 3 media were not inactivated after 3 days of storage. The pH, buffering capacity, surface tension and particle size at t = 72 hours were close to those at t = 0 hours.

[0321] Table 12 - Properties of biorelevant media after preparation according to the examples. The media were stored at room temperature for 72 hours.

[0322]

[0323] The present invention provides a biorelevant dissolution composition for in vitro dissolution and solubility studies and a method for obtaining a simulated medium from a precursor concentrate. The simulated gastric medium is modeled based on the gastric contents after consuming high-fat and low-fat meals and substitutes, containing higher fat content (up to 200g fat) and lower fat content (1g fat). The present invention meets the practical needs of conducting biorelevant tests in the fed state while conducting fasting state media, allowing for more accurate in vitro evaluations after eating, such as evaluating the effects of food on drugs after FDA standard meals. Food effects also include in vitro dissolution testing of drug products in simulated gastric fluid (FEDGAS), which contains, for example, 1g fat, which is present in, for example, a cup of milk tea, supporting improved in vitro and in vivo correlation. It is convincing and advantageous to use the biorelevant medium instead of the prior art medium; in particular, it is used to characterize pharmacologically active / related substances, such as drug compounds, oral dosage forms, etc. In addition, investigating the effects of food in the stomach meets the practical needs for drug characterization, such as in lead optimization and general formulation development, thereby saving cost and time.

[0324] The present invention provides unexpectedly stable, easily water-dispersible biorelevant concentrate compositions. The biorelevant concentrates and buffered concentrate compositions can be used to produce easily filterable and highly stable biorelevant test media that simulate fed gastric fluid after consuming, for example, a high-fat to low-fat FDA diet. Therefore, the present invention is clearly advantageous and has industrial applicability. The proposed simulated gastric fluid in the fed state can be used for biorelevant dissolution and dissolution studies to analyze drugs and drug products.

Claims

1. A biorelevant precursor composition for preparing a filterable composition that simulates the gastric fluid of a mammal in a fed state after being dispersed, diluted or suspended in an aqueous medium, wherein the biorelevant precursor composition comprises a substantially solid or solid-like concentrate, a viscous gel-like concentrate or a liquid fat dispersion or concentrate, characterized by comprising at least one major ingredient selected from the following major ingredient group: i) 1-70 wt% of triglyceride and / or diglyceride and / or monoglyceride or any combination thereof; ii) 1-45 wt% lecithin and / or lysolecithin; iii) 15 to 70 wt% carbohydrates; and iv) 1 to 70 wt% of water; wherein the weight ratio of total fat to total carbohydrates is 20:1 to 1:20, the total fat is from a combination of one or more main ingredients in any one of groups i) and ii), and the total carbohydrates are from a combination of one or more main ingredients in group iii); and The weight ratio of glyceride:lecithin and / or lysolecithin is 45:1 to 1:45; and In addition, it also contains at least one additional ingredient selected from the following components: (i) 0.01 to 15 wt % of fatty acid; (ii) 0.01 to 3 wt % of bile acid or bile salt; (iii) 0.01 to 2 wt % of an enzyme; (iv) 0.01 to 5 wt % of sterol; (v) 0.01 to 4 wt % of a buffer; (vi) 0.01 to 10 wt % of a penetrant; (vii) 0.01 to 30 wt % of protein or protein hydrolysate; (viii) 0.1 to 5 wt % of mucin; (ix) 0.1 to 5 wt% of a viscosity modifier; and (x) 0.01 to 3 wt% of a preservative or stabilizer, All percentages are by weight.

2. The composition of claim 1, wherein the sterol comprises cholesterol.

3. The composition of claim 1, wherein the protein comprises collagen.

4. The composition of claim 1, wherein the protein hydrolysate comprises amino acids.

5. The composition according to claim 1, wherein the preservative or stabilizer comprises a) Antioxidants, b) chelating agents, c) inorganic or organic buffers, and d) Antimicrobial agents.

6. The composition of claim 1, wherein the triglyceride is selected from the group consisting of avocado oil, canola oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, rapeseed oil, safflower oil, sesame oil, soybean oil, sunflower oil, and combinations thereof.

7. The composition of claim 1, wherein the carbohydrate comprises polysaccharides, oligosaccharides, disaccharides, monosaccharides and / or sugar alcohols.

8. The composition according to claim 7, wherein the monosaccharide is selected from glucose and fructose, the disaccharide comprises sucrose, and the polysaccharide is selected from starch, dextrin and cellulose.

9. The composition according to claim 1, wherein the composition is in the form of: a) a solid concentrate or solid-like concentrate containing 1 wt% to 10 wt% of water; or b) a viscous gel concentrate comprising 10 wt% to 25 wt% of water; or c) Liquid emulsion concentrates comprising 25 wt% to 70 wt% of water.

10. The composition of claim 1, wherein the biorelevant precursor concentrate has a water activity of less than 0.

86.

11. The composition of claim 10, wherein the biorelevant precursor concentrate has a water activity of less than 0.

70.

12. A method for preparing the bio-related precursor composition according to any one of claims 1 to 11, comprising treating: i) 1 to 70 wt% of at least one triglyceride, and / or at least one diglyceride and / or at least one monoglyceride; ii) 1 to 45 wt% of at least one lecithin and / or lysolecithin; iii) 15 to 70 wt% of at least one carbohydrate; and iv) 1 to 70 wt% of water; wherein the weight ratio of total fat to total carbohydrate is 20:1 to 1:20, and the fat is from a combination of group i) and group ii); and The weight ratio of glyceride:lecithin and / or lysolecithin is 45:1 to 1:45; and In addition, it also contains at least one additional ingredient selected from the following components: (i) 0.01 to 15 wt % of fatty acid; (ii) 0.01 to 3 wt % of bile acid or bile salt; (iii) 0.01 to 2 wt % of an enzyme; (iv) 0.01 to 5 wt % of sterol; (v) 0.01 to 4 wt % of a buffer; (vi) 0.01 to 10 wt % of a penetrant; (vii) 0.01 to 30 wt % of protein or protein hydrolysate; (viii) 0.1 to 5 wt % of mucin; (ix) 0.1 to 5 wt% of a viscosity modifier; and (x) 0.01 to 3 wt% of preservative or stabilizer By dispersing and / or homogenizing and / or controlling the water content by evaporation and / or addition or titration, a substantially solid or solid-like concentrate, a viscous gel-like concentrate or a liquid fat dispersion or concentrate is obtained.

13. The method of claim 12, wherein the sterol comprises cholesterol.

14. The method of claim 12, wherein the protein comprises collagen.

15. The method of claim 12, wherein the protein hydrolysate comprises amino acids.

16. The method according to claim 12, wherein the preservative or stabilizer comprises a) Antioxidants, b) chelating agents, c) inorganic or organic buffers, and d) Antimicrobial agents.

17. The method of claim 12, comprising using controlled evaporation after adding the aqueous solution containing at least one carbohydrate, or directly controlling the addition of the aqueous solution containing at least one carbohydrate.

18. A method for preparing a composition suitable for simulating gastric juice in a fed state of a mammal, the method comprising dispersing, diluting or suspending the biorelevant precursor composition according to any one of claims 1 to 11 in an aqueous medium.

19. A method for preparing a composition suitable for simulating gastric fluid in a fed state of a mammal according to claim 18, the method comprising dispersing or diluting the biorelevant precursor composition in an aqueous medium or a buffer concentrate, wherein the aqueous medium or buffer concentrate can be added or combined in any order to prepare an in vitro fed gastric dissolution medium at a pH required for an in vitro dissolution test.

20. The method for preparing a composition suitable for simulating gastric juice in a fed state of a mammal according to claim 19, wherein the aqueous medium used to disperse or dilute the biorelevant precursor composition for preparing a dissolution medium in a fed state in vitro may include: (i) buffered solutions to achieve the required pH, buffering capacity, and osmolarity of the biorelevant dissolution medium without further dilution; or (ii) sufficient weight or measured amounts of a biologically relevant precursor composition, sufficient weight or measured amounts of a buffer concentrate, and purified water to achieve the desired pH, buffering capacity, and osmotic pressure, which may be added and / or diluted in any order.

21. A method for preparing a composition suitable for simulating gastric juice in a fed state of a mammal according to claim 18, further comprising adding enzymes, protein hydrolysates and / or other additional components as a separate step.

22. A method for preparing a composition suitable for simulating the gastric juice of a mammal in a fed state according to claim 18, wherein the resulting dissolution medium is easily filtered through a filter with a pore size of 0.22 to 10 μm, the Z-average particle size using photon correlation spectroscopy is less than 200 nm, and the particle size distribution reflected by the polydispersity index is always less than 0.

2.

23. A kit for producing a composition suitable for simulating gastric fluid in a fed state of a mammal, the kit comprising an aqueous medium in a first container, and a biorelevant precursor composition according to any one of claims 1 to 11 in a second container.

24. A method for preparing a synthetic bio-relevant in vitro fed state dissolution medium based on the fat content of a high-fat to low-fat diet, comprising adding an aqueous medium buffered to pH 1.5 to pH 7.5, or adding 3 to 60 times of a buffer concentrate, to the bio-relevant precursor composition of any one of claims 1 to 11.